Waterloo Capital L.P. Invests $231,000 in Amgen Inc. (NASDAQ:AMGN)

Waterloo Capital L.P. bought a new stake in Amgen Inc. (NASDAQ:AMGN) in the 2nd quarter, Holdings Channel.com reports. The firm bought 738 shares of the medical research company’s stock, valued at approximately $231,000.

A number of other hedge funds and other institutional investors have also bought and sold shares of AMGN. Strategic Financial Concepts LLC bought a new position in shares of Amgen during the 2nd quarter worth approximately $26,000. Horizon Financial Services LLC bought a new position in Amgen during the first quarter worth $28,000. United Community Bank acquired a new position in shares of Amgen in the fourth quarter valued at $29,000. nVerses Capital LLC bought a new position in shares of Amgen in the second quarter valued at about $31,000. Finally, Bbjs Financial Advisors LLC acquired a new stake in shares of Amgen during the 2nd quarter worth about $33,000. Institutional investors own 76.50% of the company’s stock.

Amgen Stock Performance

Amgen stock opened at $335.95 on Friday. The company has a quick ratio of 0.89, a current ratio of 1.26 and a debt-to-equity ratio of 9.64. The stock has a market cap of $180.22 billion, a PE ratio of 47.99, a P/E/G ratio of 2.93 and a beta of 0.61. Amgen Inc. has a 12-month low of $249.70 and a 12-month high of $346.85. The business’s 50-day moving average price is $329.44 and its two-hundred day moving average price is $305.22.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings results on Tuesday, August 6th. The medical research company reported $4.97 earnings per share (EPS) for the quarter, missing the consensus estimate of $5.01 by ($0.04). Amgen had a net margin of 10.12% and a return on equity of 161.72%. The company had revenue of $8.39 billion for the quarter, compared to the consensus estimate of $8.35 billion. During the same period last year, the firm posted $5.00 earnings per share. The company’s revenue for the quarter was up 20.1% compared to the same quarter last year. As a group, analysts expect that Amgen Inc. will post 19.49 earnings per share for the current fiscal year.

Amgen Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, August 6th. Investors of record on Friday, August 16th were issued a dividend of $2.25 per share. This represents a $9.00 annualized dividend and a dividend yield of 2.68%. The ex-dividend date was Friday, August 16th. Amgen’s dividend payout ratio (DPR) is 128.57%.

Analysts Set New Price Targets

A number of research analysts recently commented on AMGN shares. Deutsche Bank Aktiengesellschaft reiterated a “hold” rating and issued a $305.00 price target (down previously from $310.00) on shares of Amgen in a research note on Wednesday, August 7th. TD Cowen lifted their price target on Amgen from $360.00 to $381.00 and gave the stock a “buy” rating in a report on Wednesday, August 7th. Bank of America boosted their price target on Amgen from $325.00 to $330.00 and gave the company a “neutral” rating in a research note on Wednesday, August 7th. Oppenheimer reissued an “outperform” rating and set a $380.00 target price on shares of Amgen in a report on Wednesday, August 7th. Finally, Royal Bank of Canada boosted their target price on shares of Amgen from $332.00 to $362.00 and gave the company an “outperform” rating in a research report on Wednesday, August 7th. Eleven investment analysts have rated the stock with a hold rating and eleven have given a buy rating to the company’s stock. According to data from MarketBeat, Amgen has a consensus rating of “Moderate Buy” and an average price target of $327.28.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.